Caption Management’s Apogee Therapeutics APGE Stock Holding History

Caption Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,800	Closed	-$191K	–	1554
2025 Q3	$191K	Sell	4,800 -5,229	-52%	-$200K	﹤0.01%	1480
2025 Q2	$436K	Buy	10,029 +7,614	+315%	+$290K	﹤0.01%	1143
2025 Q1	$90.2K	Buy	+2,415	New	+$93.4K	﹤0.01%	1365
2024 Q4	–	Sell	-7,540	Closed	-$385K	–	1440
2024 Q3	$443K	Buy	+7,540	New	+$361K	0.01%	948

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Caption Management's APGE Position: Q4 2025 in Review

Caption Management sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 4,800 shares — an estimated $191K sold.

Caption Management first reported a position in APGE in Q3 2024 and held it in 4 quarters. The position peaked at $443K in Q3 2024. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

Caption Management reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 4,800 Apogee Therapeutics shares in Q4 2025, an estimated $191K.
Caption Management first reported a position in Apogee Therapeutics in Q3 2024 and held it in 4 quarters.
Caption Management's Apogee Therapeutics position peaked at $443K in Q3 2024.
206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.